Literature DB >> 29359345

Simultaneous identification of the anaphylactoid components from traditional Chinese medicine injections using rat basophilic leukemia 2H3 and laboratory of allergic disease 2 dual-mixed/cell membrane chromatography model.

Shengli Han1,2, Yanni Lv1, Liyun Kong1, Yueming Sun1, Jia Fu1, Lingjun Li2,3, Langchong He1.   

Abstract

Traditional Chinese medicine (TCM) has been used for prevention and treatment of various diseases for many decades. TCM injection is a new dosage form, with incidence of anaphylactoid reactions increasing every year. In this study, the rat basophilic leukemia 2H3 (RBL-2H3) and laboratory of allergic disease 2 (LAD2) dual-mixed/CMC was established and was coupled with an HPLC-ESI-IT-TOF-MS system to identify the potential allergenic components in Haqing injection. Cinobufagin, piperine, osthole, praeruptorin A, and schizandrin A were screened from Haqing injection via this coupled system. Competitive binding assay showed piperine, praeruptorin A, and schizandrin A acting on MrgprX2 and cinobufagin and osthole act on the IgE receptor. The release of mediators of anaphylaxis results showed cinobufagin and osthole can cause anaphylactoid reactions by triggering the release of β-hexosaminidase and histamine via IgE-R. Praeruptorin A and schizandrin A could promote the release of β-hexosaminidase and histamine via MrgprX2 receptor. In summary, the dual-mixed/CMC model can significantly improve the efficiency of target component identification from a complex sample. When combined with competitive binding assay and validation of biological activities, this model enables accurate determination of the dual-target components, offering improved methods for quality control of TCM injections.
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Allergenic components; Competitive binding assay; Dual-mixed/cell membrane chromatography; HPLC-ESI-IT-TOF-MS; Haqing injection

Mesh:

Substances:

Year:  2018        PMID: 29359345     DOI: 10.1002/elps.201700457

Source DB:  PubMed          Journal:  Electrophoresis        ISSN: 0173-0835            Impact factor:   3.535


  2 in total

Review 1.  Therapeutic Potential of MRGPRX2 Inhibitors on Mast Cells.

Authors:  Hiroyuki Ogasawara; Masato Noguchi
Journal:  Cells       Date:  2021-10-27       Impact factor: 6.600

2.  Network pharmacology-based analysis of the mechanism of Saposhnikovia divaricata for the treatment of type I allergy.

Authors:  Xiangsheng Li; Hui Li; Tingting Wang; Yang Zhao; Yuxin Shao; Yizhao Sun; Yanfen Zhang; Zhongcheng Liu
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.